Key Highlights

  • The Defiance Daily Target 2X Long MRNA ETF (NYSEARCA:MRNX) closed at USD 148.34 on September 29, 2026, up 619.75 percent since launch, 243.30 percent over three months and 36.81 percent in a week.
  • The rally tracks Moderna (NASDAQ:MRNA), whose intismeran cancer Vaccine with Merck's Keytruda met its Phase 3 primary endpoint in high-risk melanoma on August 19.
  • Moderna shares climbed from about USD 63 on August 18 to a 52-week high near USD 195.71 on September 24, a year to date gain of roughly 561 percent.
  • Full INTerpath-001 data is scheduled for October 24, 2026 at the ESMO Congress, a binary style event for a fund that resets to 2x exposure every day.

The Catalyst: A First for mRNA in Cancer

On August 19, Merck and Moderna (NASDAQ:MRNA) said the Phase 3 INTerpath-001 trial of intismeran plus Keytruda met its primary endpoint of recurrence free survival and the key secondary endpoint of distant metastasis free survival versus Keytruda alone. The trial enrolled 1,137 patients with completely resected stage IIB to IV melanoma. The companies called it the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA based cancer therapy, and said they will engage regulators on filings. Earlier in August, the FDA approved mFLUSIVA, Moderna's first mRNA flu vaccine for adults 50 and older. The two partners split intismeran costs and profits equally.

What 2x Daily Exposure Did With It

The Defiance Daily Target 2X Long MRNA ETF (NYSEARCA:MRNX), launched February 3, 2026 with Tidal Investments as adviser, seeks twice the daily percentage change of Moderna (NASDAQ:MRNA). Defiance reported a 226.94 percent NAV return for the month to August 31 alone. Yet the long run math is not a simple doubling. The fund is up 619.75 percent since launch while Moderna stock is up roughly 561 percent this year, far from twice that figure even allowing for the fund's later start. Sharp swings, such as the pullback from about USD 174 on August 19 to USD 140.34 on August 31, compound unevenly under daily resets. Defiance lists a gross expense ratio of 1.34 percent and net Assets of about USD 29.5 million.

The Balanced Read Ahead of ESMO

Supporters argue the market is pricing an intismeran specific outcome, noting that BioNTech was up only about 5 percent this year when Moderna (NASDAQ:MRNA) had gained more than 500 percent. Skeptics point out that Moderna now carries a Market Value near USD 79 billion, while approval of one therapy does not guarantee profitability. Some published analyst price targets remain well below the share price. For the Defiance Daily Target 2X Long MRNA ETF (NYSEARCA:MRNX), the October 24 ESMO presentation is the key date: detailed efficacy numbers that disappoint could produce a single day loss twice the size of the stock's drop. Defiance warns investors could lose their entire principal within a single trading day.

Where Things Stand

Can the 2x Moderna ETF keep compounding? Only if Moderna (NASDAQ:MRNA) keeps trending with limited reversals, and that is far from assured. The Defiance Daily Target 2X Long MRNA ETF (NYSEARCA:MRNX) has turned a genuine clinical milestone into a 619.75 percent gain, but the next test is the full INTerpath-001 data on October 24. After a sevenfold move, Leverage magnifies disappointment as efficiently as it magnified success.